Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
SEOUL, South Korea, June 02, 2025--(BUSINESS WIRE)--ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration ...
Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...
Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...
Six-step framework: New guidance combines supportive care, steroids, immunosuppressants, plasma therapy, complement inhibitors, and transplants for C3G. Targeting root cause: FDA-approved and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results